RT @JonathanDavisHF: Exciting time for #HeartFailure #GDMTWorks: ARNI, SGLT2-I & ?vericiguat. Look forward to more data on Omecamtiv @jteer…
RT @JonathanDavisHF: Exciting time for #HeartFailure #GDMTWorks: ARNI, SGLT2-I & ?vericiguat. Look forward to more data on Omecamtiv @jteer…
RT @JonathanDavisHF: Exciting time for #HeartFailure #GDMTWorks: ARNI, SGLT2-I & ?vericiguat. Look forward to more data on Omecamtiv @jteer…
RT @JonathanDavisHF: Exciting time for #HeartFailure #GDMTWorks: ARNI, SGLT2-I & ?vericiguat. Look forward to more data on Omecamtiv @jteer…
RT @JonathanDavisHF: Exciting time for #HeartFailure #GDMTWorks: ARNI, SGLT2-I & ?vericiguat. Look forward to more data on Omecamtiv @jteer…
RT @JonathanDavisHF: Exciting time for #HeartFailure #GDMTWorks: ARNI, SGLT2-I & ?vericiguat. Look forward to more data on Omecamtiv @jteer…
Exciting time for #HeartFailure #GDMTWorks: ARNI, SGLT2-I & ?vericiguat. Look forward to more data on Omecamtiv @jteerlinkmd @AndrewJSauer @MKIttlesonMD @IAmDrIbrahim @mpsotka @shwinner @SusanJosephMD @AminYehyaMD @ShelleyZieroth https://t.co/nExsvgJT
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction https://t.co/94xzosIDA0
RT @ATRIUMRx: Nice review in @JACCJournals Heart Failure on omecamtiv mecarbil, including MOA, early trial experience, and design of the on…
RT @ATRIUMRx: Nice review in @JACCJournals Heart Failure on omecamtiv mecarbil, including MOA, early trial experience, and design of the on…
Nice review in @JACCJournals Heart Failure on omecamtiv mecarbil, including MOA, early trial experience, and design of the ongoing GALACTIC-HF trial: https://t.co/icc5uts948 #Cardioed #MedEd https://t.co/AyFYKQjwJZ
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
@AmpBioResearch There is info in the company’s PR and journal publication on design of #Galactic-HF. $AMGN $CYTK https://t.co/qivLbBH1Ch https://t.co/7FY0F76ml4
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
Excellent, comprehensive overview of Omecamtiv Mecarbil's clinical trial history and detailed outline of #Galactic-HF. Very optimistic for successful trial. $AMGN $CYTK https://t.co/fxnYBICFTi
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @mfiuzat: Galactic trial design and background of a novel promising therapy for HF! John Teerlink @DukeHFDoc and others now in JACC: H…
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @mfiuzat: Galactic trial design and background of a novel promising therapy for HF! John Teerlink @DukeHFDoc and others now in JACC: H…
Congratulations on a seminal publication with appropriate academia and industry author credits! Great partnership! https://t.co/3yQA0cKO8X
RT @mfiuzat: Galactic trial design and background of a novel promising therapy for HF! John Teerlink @DukeHFDoc and others now in JACC: H…
RT @mfiuzat: Galactic trial design and background of a novel promising therapy for HF! John Teerlink @DukeHFDoc and others now in JACC: H…
One of the largest HF trials conducted to date ; the community of HF hopes for another blockbuster therapy
Interesting concepts
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @BSHNurseForum: Omecamtiv Mecarbil a novel cardiac myosin activator. The trial GALACTIC trial is due to complete in 2021....
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @mfiuzat: Galactic trial design and background of a novel promising therapy for HF! John Teerlink @DukeHFDoc and others now in JACC: H…
RT @mfiuzat: Galactic trial design and background of a novel promising therapy for HF! John Teerlink @DukeHFDoc and others now in JACC: H…
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
An good read for anyone interested in cardiac pharmacology and who wants to learn more about the use of mecarbil in treating heart failure #biom4180
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @BSHNurseForum: Omecamtiv Mecarbil a novel cardiac myosin activator. The trial GALACTIC trial is due to complete in 2021....
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @mfiuzat: Galactic trial design and background of a novel promising therapy for HF! John Teerlink @DukeHFDoc and others now in JACC: H…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @mfiuzat: Galactic trial design and background of a novel promising therapy for HF! John Teerlink @DukeHFDoc and others now in JACC: H…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @CardioIAN: @CardioIAN HF Trial NEWS @MihaiTrofenciuc @Bartissimus https://t.co/ZLlmSJdwOX
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @mzkhalil: Omecamtiv Mecarbil (OM) in Chronic Heart Failure With Reduced Ejection Fraction: • OM is a myotrope, Not inotrope Interestin…
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
Omecamtiv Mecarbil (OM) in Chronic Heart Failure With Reduced Ejection Fraction: • OM is a myotrope, Not inotrope Interesting✔️🔓 https://t.co/PfjqFz7Mvm https://t.co/DwlSmYnIoT
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
【備忘】HFrEF例に対する心筋ミオシン活性化剤 “Omecamtiv Mecarbil” の予後改善作用を検討中のGALACTIC-HF試験、デザイン論文出来。来年1月終了予定。心筋細胞Ca濃度非依存性に収縮力を増強。 JACC HF https://t.co/QmsEl9tnU0
RT @BSHNurseForum: Omecamtiv Mecarbil a novel cardiac myosin activator. The trial GALACTIC trial is due to complete in 2021....
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @BSHNurseForum: Omecamtiv Mecarbil a novel cardiac myosin activator. The trial GALACTIC trial is due to complete in 2021.... https://t.c…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @mfiuzat: Galactic trial design and background of a novel promising therapy for HF! John Teerlink @DukeHFDoc and others now in JACC: H…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
Omecamtiv Mecarbil a novel cardiac myosin activator. The trial GALACTIC trial is due to complete in 2021....
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @mfiuzat: Galactic trial design and background of a novel promising therapy for HF! John Teerlink @DukeHFDoc and others now in JACC: H…
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
@CardioIAN HF Trial NEWS @MihaiTrofenciuc @Bartissimus https://t.co/ZLlmSJdwOX
RT @mfiuzat: Galactic trial design and background of a novel promising therapy for HF! John Teerlink @DukeHFDoc and others now in JACC: H…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
RT @JTLLERGO: 📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co…
📌 Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF https://t.co/EPIJx6LN6y @JACCJournals @secardiologia @SACardiologia @escardio https://t.co/sDtx5nYAzt
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @mfiuzat: Galactic trial design and background of a novel promising therapy for HF! John Teerlink @DukeHFDoc and others now in JACC: H…
RT @mfiuzat: Galactic trial design and background of a novel promising therapy for HF! John Teerlink @DukeHFDoc and others now in JACC: H…
Galactic trial design and background of a novel promising therapy for HF! John Teerlink @DukeHFDoc and others now in JACC: Heart Failure @JACCJournals #jacchf @coconnormd https://t.co/4TjSTDYXak
New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper for the #GALACTICHF trial, which explores the effect of omecamtiv mecarbil, a novel cardiac myosin activator, in chronic #HFrEF. https